Literature DB >> 12398550

Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme.

Ryuichi Sekizawa1, Souichi Ikeno, Hikaru Nakamura, Hiroshi Naganawa, Susumu Matsui, Hironobu Iinuma, Tomio Takeuchi.   

Abstract

Screening for inhibitors of the ubiquitin-proteasome pathway, considered to regulate important cellular events and linked to serious diseases as well, led to isolation of a new compound, panepophenanthrin, from the fermented broth of a mushroom strain, Panus rudis Fr. IFO 8994. This is the first inhibitor of the ubiquitin-activating enzyme, which is indispensable for the ubiquitin-proteasome pathway. The structure of panepophenanthrin was determined by NMR and X-ray crystallographic analyses as 1,3a,10-trihydroxy-10c-(3-hydroxy-3-methylbut-1-enyl)-5,5-dimethyl-1,2,3,3a,5,5a,8,9,10,10a,10b,10c-dodecahydro-4-oxa-2,3,8,9-diepoxyacephenanthrylen-7-one.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12398550     DOI: 10.1021/np020098q

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  13 in total

Review 1.  A patent review of the ubiquitin ligase system: 2015-2018.

Authors:  Xin Li; Ekinci Elmira; Sagar Rohondia; Jicang Wang; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2018-11-23       Impact factor: 6.674

2.  Homology Modelling of Human E1 Ubiquitin Activating Enzyme.

Authors:  Ghali Brahemi; Angelika M Burger; Andrew D Westwell; Andrea Brancale
Journal:  Lett Drug Des Discov       Date:  2010-01-01       Impact factor: 1.150

Review 3.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 4.  Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.

Authors:  Mariola J Edelmann; Benjamin Nicholson; Benedikt M Kessler
Journal:  Expert Rev Mol Med       Date:  2011-11-17       Impact factor: 5.600

5.  Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1).

Authors:  Dana Ungermannova; Seth J Parker; Christopher G Nasveschuk; Wei Wang; Bettina Quade; Gan Zhang; Robert D Kuchta; Andrew J Phillips; Xuedong Liu
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

Review 6.  Strategies to Target ISG15 and USP18 Toward Therapeutic Applications.

Authors:  Daniel Jiménez Fernández; Sandra Hess; Klaus-Peter Knobeloch
Journal:  Front Chem       Date:  2020-01-21       Impact factor: 5.221

7.  Inhibition of the Ubiquitin-Activating Enzyme UBA1 Suppresses Diet-Induced Atherosclerosis in Apolipoprotein E-Knockout Mice.

Authors:  Jiawei Liao; Xiaolei Yang; Qiuyue Lin; Shuang Liu; Yunpeng Xie; Yunlong Xia; Hui-Hua Li
Journal:  J Immunol Res       Date:  2020-03-20       Impact factor: 4.818

Review 8.  Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways.

Authors:  Brenda A Schulman; J Wade Harper
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-08       Impact factor: 94.444

9.  Identification and mechanistic studies of a novel ubiquitin E1 inhibitor.

Authors:  Dana Ungermannova; Seth J Parker; Christopher G Nasveschuk; Douglas A Chapnick; Andrew J Phillips; Robert D Kuchta; Xuedong Liu
Journal:  J Biomol Screen       Date:  2012-01-24

Review 10.  Fungal Secondary Metabolites as Inhibitors of the Ubiquitin-Proteasome System.

Authors:  Magdalena Staszczak
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.